Displaying drugs 14676 - 14700 of 15040 in total
Thiamphenicol
Experimental
Investigational
(4-ETHYLPHENYL)SULFAMIC ACID
Experimental
5-(3-(2,6-dichloro-4-(4,5-dihydro-2-oxazolyl)phenoxy)propyl)-3-methyl isoxazole
5-(3-(2,6-dichloro-4-(4,5-dihydro-2-oxazolyl)phenoxy)propyl)-3-methyl isoxazole is a solid. This compound belongs to the phenol ethers. These are aromatic compounds containing an ether group substituted with a benzene ring. Known drug targets of 5-(3-(2,6-dichloro-4-(4,5-dihydro-2-oxazolyl)phenoxy)propyl)-3-methyl isoxazole include genome polyprotein.
Experimental
Etofibrate
Etofibrate is a fibrate produced by the combination of clofibrate ester linked to niacin. These components separate in the body slowly allowing for pharmacokinetics similar to controlled-release formulations.
Experimental
Dapaconazole
Dapaconazole has been used in trials studying the treatment of Tinea Pedis.
Investigational
Dalcetrapib
Dalcetrapib is under investigation for the treatment of Acute Coronary Syndrome.
Investigational
Azeliragon
Azeliragon has been used in trials studying the treatment of Alzheimer's Disease.
Investigational
Ritanserin
Ritanserin has been used in trials studying the treatment of Cocaine-Related Disorders.
Investigational
2,2-bis(4-hydroxy-3-tert-butylphenyl)propane
TBD has been used in trials studying the treatment of Adenocarcinoma.
Investigational
Cibenzoline
Experimental
Budipine
Experimental
Sequifenadine
Experimental
Picloxydine
Experimental
Sulbentine
Experimental
Xibornol
Experimental
Clofibride
Experimental
Bisoxatin acetate
Experimental
Motexafin lutetium
Motexafin lutetium (MLu) is a second-generation photosensitizer for photodynamic therapy (PDT) of cancer. It belongs to the family of drugs called metallotexaphyrins. Also called lutetium texaphyrin. Motexafin lutetium is a pentadentate aromatic metallotexaphyrin with photosensitizing properties.
Investigational
Displaying drugs 14676 - 14700 of 15040 in total